arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Zentalis Pharmaceuticals, Inc.

ZNTL
$2.86 ▼ -0.22 (-6.99%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Zentalis Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $204.0M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -31.0%
FCF / Share $-0.52
Trailing P/E
Price / Book 1.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-42.29M
↓ -57.3%
Operating Margin Operating profit as % of sales
-185.6%
↓ -203.9%
FCF / Share Free cash flow per share
$-0.52
↓ -11.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
14
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters